User profiles for HIDESAKU ASAKURA

Hidesaku ASAKURA

Kanazawa University Hospital
Verified email at staff.kanazawa-u.ac.jp
Cited by 8318

[HTML][HTML] COVID-19-associated coagulopathy and disseminated intravascular coagulation

H Asakura, H Ogawa - International journal of hematology, 2021 - Springer
The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression
of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The …

Expert consensus for the treatment of disseminated intravascular coagulation in Japan

H Wada, H Asakura, K Okamoto, T Iba, T Uchiyama… - Thrombosis research, 2010 - Elsevier
The present report from The Japanese Society of Thrombosis and Hemostasis provides an
expert consensus for the treatment of disseminated intravascular coagulation (DIC) in Japan. …

[HTML][HTML] Classifying types of disseminated intravascular coagulation: clinical and animal models

H Asakura - Journal of intensive care, 2014 - Springer
Disseminated intravascular coagulation (DIC) has a common pathogenesis in terms of
persistent widespread activation of coagulation in the presence of underlying disease, but the …

[HTML][HTML] Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis

H Asakura, H Takahashi, T Uchiyama, Y Eguchi… - Thrombosis …, 2016 - Springer
Disseminated intravascular coagulation (DIC) is a serious disease that, in the presence of
underlying disease, causes persistent, generalized, marked coagulation activation. Early …

Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH …

H Wada, EC Gabazza, H Asakura… - American journal of …, 2003 - Wiley Online Library
We compared the criteria set by the International Society of Thrombosis and Hemostasis (ISTH)
for the diagnosis of disseminated intravascular coagulation (DIC) with the criteria of the …

Potential of heparin and nafamostat combination therapy for COVID‐19

H Asakura, H Ogawa - Journal of Thrombosis and Haemostasis, 2020 - jthjournal.org
Tang et al recently reported that, in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2),
heparin anticoagulant therapy lowers the mortality rate in patients who present …

[HTML][HTML] Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential

T Ito, J Thachil, H Asakura, JH Levy, T Iba - Critical Care, 2019 - Springer
Thrombomodulin plays a vital role in maintaining intravascular patency due to its anticoagulant,
antiinflammatory, and cytoprotective properties. However, under pathological conditions …

Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients

S Gando, H Wada, H Asakura, T Iba… - Clinical and applied …, 2005 - journals.sagepub.com
New Japanese diagnostic criteria were prepared for disseminated intravascular coagulation
(DIC) in critically ill patients and their usefulness was compared with the criteria of the …

A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation

…, H Takahashi, J Takamatsu, H Asakura… - International journal of …, 2002 - Springer
A randomized prospective double-blind trial was performed to compare the safety and
efficacy of human activated protein C (APC) and unfractionated heparin for the treatment of …

[HTML][HTML] Coagulopathy and fibrinolytic pathophysiology in COVID-19 and SARS-CoV-2 vaccination

S Yamada, H Asakura - International Journal of Molecular Sciences, 2022 - mdpi.com
Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and is frequently complicated by thrombosis. In some cases of …